Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

@article{Gibney2013ClinicalDO,
  title={Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies},
  author={Geoffrey Thomas Gibney and Jonathan S. Zager},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2013},
  volume={9},
  pages={893 - 899}
}
  • G. Gibney, J. Zager
  • Published 17 June 2013
  • Biology, Medicine, Chemistry
  • Expert Opinion on Drug Metabolism & Toxicology
Introduction: The development of selective BRAF inhibitors in patients with metastatic BRAF V600 mutant melanoma has proven to be an effective therapeutic strategy. While vemurafenib was the first approved BRAF inhibitor for this indication, another selective BRAF inhibitor, dabrafenib, has demonstrated efficacy in patients with BRAF mutant melanoma, including those with active brain metastases and other malignancies. Areas covered: This review covers the current role of BRAF inhibitors in… 
Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation
TLDR
Dabrafenib has demonstrated comparable efficacy to vemurafenib in BRAF V600E mutant melanoma patients, and is well tolerated in patients with metastatic melanoma, including patients with brain metastases.
New drug targets in metastatic melanoma
TLDR
Current molecular targeted treatment options, immunotherapy and promising ongoing research to develop new strategies to treat melanoma are discussed.
Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
TLDR
The combination of A100 with a BRAF inhibitor could be a potential strategy to treat melanoma patients with BRAF mutations by suppressing in vitro cell proliferation and three- dimensional matrigel growth.
Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
TLDR
The case of a 77-year-old gentleman affected by a metastatic clear cell carcinoma of the kidney and a malignant melanoma with liver and lung metastases is reported, representing the first evidence of sunitinib activity in KIT wild-type melanoma.
BRAF inhibitors: From the laboratory to clinical trials.
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
TLDR
It is established that RAC1 amplification, with or without mutation, is sufficient to drive cell proliferation and resistance to BRAF inhibition, and polyploidy leading to increased expression of specific genes, particularly those located on chromosome 7, should be considered when analyzing aggressive thyroid tumor samples and in further treatments.
Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
TLDR
Findings indicate that RSK-independent phosphorylation of rpS6 confers resistance to MAPK pathway inhibitors in BRAF-mutant melanoma, and that mTOR inhibitor-based regimens may provide alternative strategies to overcome this acquired resistance.
Systemic Therapy for Advanced Metastatic Thyroid Cancer
TLDR
FDA approval of new therapeutic agents in metastatic, radioiodine-refractory DTC represents a major breakthrough and further research is needed to identify new therapies with better response and toxicity profiles as well as to determine how to best utilize these new agents safely either sequentially or in combination.
Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
  • L. Zimmer, U. Hillen, D. Schadendorf
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Malignant melanocytic tumors might develop with increased frequency in patients treated with selective BRAF inhibitors supporting a mechanism of BRAF therapy-induced growth and tumorigenesis.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
Inhibition of mutated, activated BRAF in metastatic melanoma.
TLDR
Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
BRAF inhibitor activity in V600R metastatic melanoma.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
TLDR
The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
TLDR
Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
TLDR
Distinct clinical phenotypes exist for melanomas bearing NRAS and BRAF mutations, whether considered together or separately, and are associated with features known to predict aggressive tumor behavior, most evident at earlier stages of disease progression.
...
1
2
3
4
...